Winter is approaching, folks, which means a lot of things are on the horizon.
The holidays are coming, so shopping will be on everyone’s mind.
For homeowners, shoveling snow, new cracks in the driveway, and what to do with the kids during their two weeks off school will be concerns.
However, another concern will be seasonal sicknesses — namely, the flu.
Each year, about one in five Americans fall ill with the flu, and upwards of 30,000 people actually succumb to what most consider little more than a glorified common cold.
Most of those deaths happen within the two most vulnerable age groups: very young children and the elderly.
Fear Can Be Deadly
The main reason behind these infections, lost productivity, and even lost lives is so simple and avoidable that it would be funny if the results weren’t so horrifying… People are scared of needles.
That childish instinct to avoid getting your shots is no joke. It’s a diagnosable disorder called trypanophobia, and millions of Americans, young and old, suffer from it.
This phobia, as well as the resulting health problems people inflict on themselves because of it, stems from the needle itself — most likely from early childhood memories of getting shots.
Sadly, this is a problem that has plagued any medical procedure involving the use of hypodermic syringes since their very advent more than 150 years ago.
We all hate them (those of us who don’t are arguably more deviant than those who avoid them altogether), but we all accept that they’re necessary evils of modern life.
Without syringes, life-saving, disease-killing vaccines would not be deliverable.
Without syringes, some of the most important medical tests in existence would not be possible.
Without syringes, the quality of life of billions of people across the world would not be what it is today.
And yet despite their importance, syringes have not changed in design since they were created by a couple of European physicians in the mid-1850s.
Reinventing an Icon
The same three basic elements — the tube, the plunger, and the needle — still look and operate almost exactly as they did in the first crude brass models used by doctors in the years leading up to the American Civil War.
Along with those basic components, all of the shortcomings of this device have remained unchanged.
They’re still imprecise, often missing their target blood vessels — despite the best efforts of the nurse or doctor — and causing painful and infectious abscesses.
They’re still dangerous even when they’re not being used — they cost in excess of $3 billion in personal injury every year from accidental puncture wounds.
And they’re still terrifying to children and adults alike.
But as crucial as they are to modern medical science, there was no way around them.
Until now.
Join Wealth Daily today for FREE. We’ll keep you on top of all the hottest investment ideas before they hit Wall Street. Become a member today, and get our latest free report: “The Top Three Biotech Stocks”
It contains full details on biotech stocks that are hidden in the haystack.
Right now, a small American biotech company is taking the lead in bringing injection technology into the 21st century.
And let’s get one thing straight: This isn’t just some improvement or an added bell or whistle.
This is a total redesign.
The plunger has been replaced by a computer-controlled pump, which will never allow fluids to be introduced too quickly.
The needle has been equipped with a tissue density sensor, which prevents it from ever missing its mark.
And the appearance of the whole thing has changed so much that few people will ever associate it with the old, iconic, fear-inspiring device.
Not Your Typical Biotech
This company has been around for 25 years, but injection technology isn’t one of a long list of its product types — it’s the company’s only product type.
It specializes in this and nothing else.
Most exciting of all, the company already has FDA approval to sell its devices here in the States and in 40 foreign countries.
However, the excitement is just getting started.
You see, the company is small — just $50 million in total market capitalization.
And right now, it’s waiting for the FDA to approve its devices for some key medical procedures that could double or even triple its revenue in short order.
Make no mistake about it, folks — this is one of those biotech companies that is destined to make a major impact on the industry.
Whether its future holds triple-digit gains or an even more lucrative buyout, one thing is for sure: This company’s products will change the face of modern medicine in the coming years.
To learn more about the company and the technology it’s already transformed, click here for the full report.
Fortune favors the bold,
Alex Koyfman
Check us out on YouTube!His flagship service, Microcap Insider, provides market-beating insights into some of the fastest moving, highest profit-potential companies available for public trading on the U.S. and Canadian exchanges. With more than 5 years of track record to back it up, Microcap Insider is the choice for the growth-minded investor. Alex contributes his thoughts and insights regularly to Energy and Capital. To learn more about Alex, click here.
